Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if Imbruvica (ibrutinib) alone and then
in combination with Opdivo (nivolumab) can control NSCLC in patients who have received
previous chemotherapy treatment.